Findings highlight opportunity for shared decision-making to improve treatment planning, with more than 90% of patients currently on injectables willing to switch to a new oral therapy with equivalent efficacy… Read More
In Canada, LEQEMBI® is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein… Read More
In areas of high impact, 72% of patients with scalp psoriasis and 85% with genital psoriasis treated with icotrokinra achieved site-specific clear or almost clear skin at Week 52 in… Read More
KIRKLAND, QC – Pfizer Canada is pleased to announce that ABRYSVO, its vaccine for the prevention of Respiratory Syncytial Virus (RSV), has been selected for public funding in multiple provinces… Read More
Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancer 64% overall… Read More
